ISSN: 1859 - 2872
Assessment of clinical, laboratory characteristics and some related factors of recurrent in patient with transverse myelitis
Main Article Content
Keywords
Abstract
Summary
Objective: To describe the clinical and laboratory characteristics, some prognosis factors of patients with transverse myelitis. Subject and method: A retrospective descriptive study of 25 patients with Neurology Department of 108 Military Central Hospital from January, 2014 to May, 2019. Result: The average age of patients was 44.8 ± 13.4 years old with the percentage of women was 52% and the duration of the plateau phase of symptoms under 2 weeks was 60%. The percentage of the lesion in the thoracic spinal cord was 61.9%, the lesion which was up to the medullary was 14.3% and the lesion which was longer than 2 vertebral segments was 90.5%. The changes in the cerebrospinal fluid (CSF) was seen in 88% of patients with 44% increase in the number of blood cells, 56% increase in the protein level and 68% with positive Pandy’s reaction. In the following-up time of average 34 months, there was 59% of recurrence. Patients with these factors including elevated CSF protein level, the lesion longer than 2 vertebral segments were at higher risk of recurrence. Patients with recurrence had worse functional status (mRs: 3.0 ± 1,9 vs 1.67 ± 1.0, p<0.01). Conclusion: Patients with the lesion longer than 2 vertebral segments and elevated CSF protein level were at higher risk of recurrence. Patients with recurrence had worse functional status.
Keywords: Transverse myelitis, recurrence.
Article Details
References
2. Zalewski NL, Flanagan EP, and Keegan BM (2018) Evaluation of idiopathic transverse myelitis revealing specific myelopathy diagnoses. Neurology 90(2): 96.
3. Kitley J et al (2013) Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies. JAMA Neurology 70(11): 1375-1381.
4. Presas-Rodríguez S, Hervás-Garcíaa JV, Massuet-Vilamajó A, Ramo-Telloa C (2016) Myelitis: Differences between multiple sclerosis and other aetiologies. Neurología 31: 71-75.
5. Aijaz Ali, Amir Riaz et al (2019) Assessment of clinical outcomes in patients presenting with transverse myelitis: A tertiary care experience from a developing country. Cureus 11(3): 4342.
6. Sato DK, Callegaro D, Lana-Peixoto MA, et al (2014) Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 82(6): 474-481.
7. Dubey D et al (2019) Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody. JAMA neurology 76(3): 301-309.
8. Barnes G et al (2002) Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology 59: 499-505.
9. Kimbrough DJ et al (2014) Predictors of recurrence following an initial episode of transverse myelitis. Neurol Neuroimmunol Neuroinflammation 1(1): 4.
10. Alvarenga MP et al (2010) The clinical course of idiopathic acute transverse myelitis in patients from Rio de Janeiro. Journal of Neurology 257(6): 992-998.
11. Gajofatto A et al (2010) Assessment of outcome predictors in first-episode acute myelitis: A retrospective study of 53 cases. Archives of Neurology 67(6): 724-730.
12. Tobin WO, Weinshenker BG et al (2014) Longitudinally extensive transverse myelitis. Current opinion in neurology 27(3): 279-289.
13. Apostolos-Pereira S et al (2013) Differential diagnosis of longitudinally extensive transverse myelitis (P02.109). Neurology 80(7): 02109.
14. Abdullah S, Wong WF, and Tan C (2017) The prevalence of anti-aquaporin 4 antibody in patients with idiopathic inflammatory demyelinating diseases presented to a Tertiary Hospital in Malaysia: Presentation and prognosis. Multiple Sclerosis International: 1-6.
15. Bulut E et al (2019) MRI predictors of recurrence and outcome after acute transverse myelitis of unidentified etiology. AJNR Am J Neuroradiol 40(8): 1427-1432.
Article Sidebar
